{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:30:42Z","timestamp":1706805042096},"reference-count":36,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,4,1]]},"DOI":"10.1248\/bpb.b20-00609","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T22:06:51Z","timestamp":1617228411000},"page":"478-484","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Palonosetron on Nausea and Vomiting Induced by Multiple-Day Chemotherapy: A Retrospective Study"],"prefix":"10.1248","volume":"44","author":[{"given":"Hirofumi","family":"Hamano","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisato","family":"Mitsuhashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School"},{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaito","family":"Tsujinaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Niimura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Hayama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nihon University Itabashi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nihon University Itabashi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Takechi","sequence":"additional","affiliation":[{"name":"Department of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Yagi","sequence":"additional","affiliation":[{"name":"Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Chuma","sequence":"additional","affiliation":[{"name":"Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Horinouchi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Tokushima Bunri Universityy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Shinomiya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Tokushima Bunri Universityy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Kirino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yanagawa","sequence":"additional","affiliation":[{"name":"Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School"},{"name":"Department of Pharmacy, Tokushima University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Popovic M, Warr DG, Deangelis C, Tsao M, Chan KK, Poon M, Yip C, Pulenzas N, Lam H, Zhang L, Chow E. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support. Care Cancer<\/i>, 22<\/b>, 1685\u20131697 (2014)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Browning KN. Role of central vagal 5-HT3 receptors in gastrointestinal physiology and pathophysiology. Front. Neurosci<\/i>, 9<\/b>, 413 (2015).","DOI":"10.3389\/fnins.2015.00413"},{"key":"3","unstructured":"3) Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J. Clin. Oncol.<\/i>, 9<\/b>, 675\u2013678 (1991)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N. Engl. J. Med.<\/i>, 332<\/b>, 1\u20135 (1995).","DOI":"10.1056\/NEJM199501053320101"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J. Clin. Pharmacol.<\/i>, 44<\/b>, 520\u2013531 (2004).","DOI":"10.1177\/0091270004264641"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Wong EH, Clark R, Leung E, Loury D, Bonhaus DW, Jakeman L, Parnes H, Whiting RL, Eglen RM. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.<\/i> Br. J. Pharmacol.<\/i>, 114<\/b>, 851\u2013859 (1995).","DOI":"10.1111\/j.1476-5381.1995.tb13282.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Maemondo M, Masuda N, Sekine I, Kubota K, Segawa Y, Shibuya M, Imamura F, Katakami N, Hida T, Takeo S. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann. Oncol.<\/i>, 20<\/b>, 1860\u20131866 (2009).","DOI":"10.1093\/annonc\/mdp195"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Segawa Y, Aogi K, Inoue K, Sano M, Sekine I, Tokuda Y, Isobe H, Ogura T, Tsuboi M, Atagi S. A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. Ann. Oncol.<\/i>, 20<\/b>, 1874\u20131880 (2009).","DOI":"10.1093\/annonc\/mdp243"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol.<\/i>, 17<\/b>, 1441\u20131449 (2006).","DOI":"10.1093\/annonc\/mdl137"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med.<\/i>, 316<\/b>, 1435\u20131440 (1987).","DOI":"10.1056\/NEJM198706043162302"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David Crawford E, Vogelzang N, Trump D, Loehrer PJ Sr. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors. Cancer<\/i>, 97<\/b>, 1869\u20131875 (2003).","DOI":"10.1002\/cncr.11271"},{"key":"12","unstructured":"12) Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJ, Cook PA, Stenning SP, Mason M. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br. J. Cancer<\/i>, 93<\/b>, 178\u2013184 (2005)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J. Natl. Compr. Canc. Netw.<\/i>, 5<\/b>, 51\u201359 (2007).","DOI":"10.6004\/jnccn.2007.0007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Affronti ML, Bubalo J. Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy. Cancer Manag. Res.<\/i>, 6<\/b>, 329\u2013337 (2014).","DOI":"10.2147\/CMAR.S68102"},{"key":"15","unstructured":"15) Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ. 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support. Care Cancer<\/i>, 25<\/b>, 303\u2013308 (2017)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support. Care Cancer<\/i>, 15<\/b>, 1293\u20131300 (2007).","DOI":"10.1007\/s00520-007-0255-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F, Bianchini C, Perrone T. Palonosetron (Aloxi\u00ae<\/sup>) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support. Care Cancer<\/i>, 17<\/b>, 205\u2013209 (2009).","DOI":"10.1007\/s00520-008-0510-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ioroi T, Furukawa J, Kume M, Hirata S, Utsubo Y, Mizuta N, Miyake H, Fujisawa M, Hirai M. Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy. Support. Care Cancer<\/i>, 26<\/b>, 1419\u20131423 (2018).","DOI":"10.1007\/s00520-017-3967-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Feinberg B, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D. Impact of initiating antiemetic prophylaxis with palonosetron versus<\/i> ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. Support. Care Cancer<\/i>, 20<\/b>, 615\u2013623 (2012).","DOI":"10.1007\/s00520-011-1140-x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) B\u00f6hlen D, Borner M, Sonntag RW, Fey MF, Studer UE. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J. Urol.<\/i>, 161<\/b>, 1148\u20131152 (1999).","DOI":"10.1016\/S0022-5347(01)61615-X"},{"key":"21","unstructured":"21) Okada N, Hanafusa T, Abe S, Sato C, Nakamura T, Teraoka K, Abe M, Kawazoe K, Ishizawa K. Evaluation of the risk factors associated with high-dose chemotherapy-induced dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation: possible usefulness of cryotherapy in dysgeusia prevention. Support. Care Cancer<\/i>, 24<\/b>, 3979\u20133985 (2016)."},{"key":"22","unstructured":"22) Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol.<\/i>, 14<\/b>, 1570\u20131577 (2003)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Constenla M. 5-HT3<\/sub> Receptor antagonists for prevention of late acute-onset emesis. Ann. Pharmacother.<\/i>, 38<\/b>, 1683\u20131691 (2004).","DOI":"10.1345\/aph.1D191"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? systematic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol.<\/i>, 23<\/b>, 1289\u20131294 (2005).","DOI":"10.1200\/JCO.2005.04.022"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kilpatrick GJ, Jones BJ, Tyers MB. Identification and distribution of 5-HT3<\/sub> receptors in rat brain using radioligand binding. Nature<\/i>, 330<\/b>, 746\u2013748 (1987).","DOI":"10.1038\/330746a0"},{"key":"26","unstructured":"26) Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3<\/sub> receptor antagonist: results of a phase III, single-dose trial versus<\/i> dolasetron. Cancer<\/i>, 98<\/b>, 2473\u20132482 (2003)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, Snyder SH, Slusher BS. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth. Analg.<\/i>, 107<\/b>, 469\u2013478 (2008).","DOI":"10.1213\/ane.0b013e318172fa74"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, Slusher BS. Palonosetron triggers 5-HT3<\/sub> receptor internalization and causes prolonged inhibition of receptor function. Eur. J. Pharmacol.<\/i>, 626<\/b>, 193\u2013199 (2010).","DOI":"10.1016\/j.ejphar.2009.10.002"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Hothersall JD, Moffat C, Connolly CN. Prolonged inhibition of 5-HT3<\/sub> receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization. Br. J. Pharmacol.<\/i>, 169<\/b>, 1252\u20131262 (2013).","DOI":"10.1111\/bph.12204"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, Slusher BS. The antiemetic 5-HT3<\/sub> receptor antagonist palonosetron inhibits substance p-mediated responses in vitro<\/i> and in vivo.<\/i> J. Pharmacol. Exp. Ther.<\/i>, 335<\/b>, 362\u2013368 (2010).","DOI":"10.1124\/jpet.110.166181"},{"key":"31","unstructured":"31) Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S. Palonosetron plus dexamethasone versus<\/i> granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol.<\/i>, 10<\/b>, 115\u2013124 (2009)."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Sugimoto Y, Yamada J, Yoshikawa T, Noma T, Horisaka K. Effects of peripheral 5-HT2<\/sub> and 5-HT3<\/sub> receptor agonists on food intake in food-deprived and 2-deoxy-D-glucose-treated rats. Eur. J. Pharmacol.<\/i>, 316<\/b>, 15\u201321 (1996).","DOI":"10.1016\/S0014-2999(96)00660-7"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Dourish CT, Clark ML, Fletcher A, Iversen SD. Evidence that blockade of post-synaptic 5-HT1<\/sub> receptors elicits feeding in satiated rats. Psychopharmacology<\/i>, 97<\/b>, 54\u201358 (1989).","DOI":"10.1007\/BF00443413"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hayes MR, Savastano DM, Covasa M. Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT3 receptors. Physiol. Behav.<\/i>, 82<\/b>, 663\u2013669 (2004).","DOI":"10.1016\/j.physbeh.2004.06.001"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Hayes MR, Chory FM, Gallagher CA, Covasa M. Serotonin type-3 receptors mediate cholecystokinin-induced satiation through gastric distension. Am. J. Physiol. Regul. Integr. Comp. Physiol.<\/i>, 291<\/b>, R115\u2013R123 (2006).","DOI":"10.1152\/ajpregu.00002.2006"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3<\/sub> receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment. Pharmacol. Ther.<\/i>, 14<\/b>, 775\u2013782 (2000).","DOI":"10.1046\/j.1365-2036.2000.00762.x"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/4\/44_b20-00609\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T03:29:18Z","timestamp":1617420558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/4\/44_b20-00609\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-00609","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}